LSPCX | MBXCX | LSPCX / MBXCX | |
Total Expense Ratio | 4.61 | 3.03 | 152% |
Annual Report Gross Expense Ratio | 4.64 | 3.03 | 153% |
Fund Existence | 12 years | 10 years | - |
Gain YTD | 4.618 | 3.359 | 137% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 71.1M | 8.45B | 1% |
Annual Yield % from dividends | 7.56 | 0.92 | 820% |
Returns for 1 year | 1.39 | 4.25 | 33% |
Returns for 3 years | 15.28 | 5.27 | 290% |
Returns for 5 years | 41.30 | 42.96 | 96% |
Returns for 10 years | 28.71 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
AFDRX | 56.64 | 0.36 | +0.64% |
American Century Large Cap Equity R | |||
RYCFX | 48.07 | 0.19 | +0.40% |
Rydex Biotechnology C | |||
LRSCX | 14.95 | 0.06 | +0.40% |
Lord Abbett Small Cap Value A | |||
MXEVX | 12.34 | 0.03 | +0.24% |
Empower Core Strategies Intl Eq Inv | |||
DFIEX | 19.49 | -0.02 | -0.10% |
DFA International Core Equity 2 I |